New blood pressure pill put to the test in UAE patients
NCT ID NCT07465666
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at how well a drug called ARNi (sacubitril/valsartan) lowers blood pressure in 500 adults with hypertension in the United Arab Emirates. Researchers will compare it to standard treatments like ACE inhibitors and calcium channel blockers. The goal is to see if ARNi works better in everyday medical practice, not just in controlled lab settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacubitril/valsartan (ARNi)
What this could lead to
If successful, this could show that ARNi is more effective than standard blood pressure medications for people in the UAE, potentially improving treatment guidelines.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to one region, so findings may not apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact